| Identification | Back Directory | [Name]
4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid | [CAS]
171746-21-7 | [Synonyms]
CD 3106
AGN 193109
AGN 193109 SodiuM Salt
4-((5,5-Dimethyl-8-p-tolyl-5,6-dihydronaphthalen-2-yl)ethynyl)benzoic acid
4-{[5,5-diMethyl-8-(4-Methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid
4-[2-[5,6-Dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl]ethynyl]benzoic Acid
Benzoic acid, 4-[2-[5,6-dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl]ethynyl]- | [Molecular Formula]
C28H24O2 | [MDL Number]
MFCD00943817 | [MOL File]
171746-21-7.mol | [Molecular Weight]
392.49 |
| Chemical Properties | Back Directory | [Melting point ]
246-255?C | [Boiling point ]
564.5±50.0 °C(Predicted) | [density ]
1.21±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
Chloroform (Slightly, Heated), DMSO (Slightly, Sonicated) | [form ]
Solid | [pka]
4.08±0.10(Predicted) | [color ]
Off-White to Pale Yellow | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White Solid | [Uses]
As a retinoic acid receptor (RAR) antagonist, 4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid can be used for treating chemotherapy and radiation therapy side effects.
| [Biological Activity]
AGN 193109 is an orally active retinoic acid receptor (RAR) antagonist th at targets all three RAR subtypes with higher affinity (RARα/β/γ Kd = 2 nM) than all-trans retinoic acid/ATRA (RARα/β/γ Kd = 9/12/19 nM). AGN 193109 potently antagonizes against ATRA-induced transcription in RARαRARβand RARγ transfected CV-1 cells (by 85%62%and 100%respectivelyby equal molar AGN 193109 against ATRA). AGN 193109 is also widely employeed to block RAR-mediated physiological and pathalogical processes in mice and rats in vivo via oral (1-10 mg/kg) or topical (0.3-36 μmol/kg) administration. | [in vivo]
AGN 193109 (1.15 μmol/kg) does not causes overt toxicity and has no effect on spleen weight on the mice, but it suppresses TTNPB-induced increase in spleen weight of the mice. AGN 193109 also significantly reduces the cutaneous toxicity induced by ATRA. AGN 193109 (0.30 or 1.20 μmol/kg) by topical treatment significantly reduces both weight loss and cutaneous toxicity caused by oral TTNPB cotreatment[3]. | [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
TaiChem Taizhou Limited
|
| Tel: |
052386810091 |
| Website: |
https://www.chemicalbook.com/supplier/11410902/1.htm |
|